Charles Schwab Investment Management Inc Adagio Therapeutics, Inc. Transaction History

Charles Schwab Investment Management Inc

$515 Billion
Q3 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 210,749 shares of ADGI stock, worth $697,579. This represents 0.0% of its overall portfolio holdings.

Number of Shares

210,749

Previous 500,061 57.86%

Holding current value

$697,579

Previous $1.66 Million 57.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	N/A	-289,312 Reduced 57.86%	210,749 $697,000
Q2 2024 Aug 12, 2024	BUY	N/A	188,807 Added 60.66%	500,061 $1.66 Million
Q1 2024 May 08, 2024	BUY	N/A	7,339 Added 2.41%	311,254 $1.03 Million
Q4 2023 Feb 06, 2024	BUY	N/A	36,435 Added 13.62%	303,915 $1.01 Million
Q3 2023 Nov 08, 2023	SELL	N/A	-12,633 Reduced 4.51%	267,480 $885,000
Q2 2023 Aug 09, 2023	SELL	N/A	-116,352 Reduced 29.35%	280,113 $927,000
Q1 2023 May 11, 2023	SELL	N/A	-4,053 Reduced 1.01%	396,465 $1.31 Million
Q4 2022 Feb 13, 2023	BUY	$3.08 - $4.05 $26,512 - $34,862	8,608 Added 2.2%	400,518 $1.33 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $549,340 - $893,371	184,963 Added 89.38%	391,910 $1.23 Million
Q2 2022 Aug 15, 2022	SELL	$2.54 - $4.52 $5,186 - $9,229	-2,042 Reduced 0.98%	206,947 $679,000
Q1 2022 May 13, 2022	BUY	$3.81 - $10.77 $271,222 - $766,683	71,187 Added 51.66%	208,989 $953,000
Q4 2021 Feb 11, 2022	BUY	$6.35 - $47.04 $23,774 - $176,117	3,744 Added 2.79%	137,802 $1 Million
Q3 2021 Nov 16, 2021	BUY	$20.88 - $56.08 $2.8 Million - $7.52 Million	134,058 New	134,058 $5.66 Million

Others Institutions Holding ADGI

# of Institutions

Shares Held

63.9M

Call Options Held

2.3K

Put Options Held

2.1K

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Adagio Therapeutics, Inc. Transaction History